• 구독신청
  • My스크랩
  • 지면신문
FNTIMES 대한민국 최고 금융 경제지
ad

Dividends and Buybacks: How Emart Broke Free From Retail's Valuation Trap [The Answer Is TSR]

박슬기 기자

seulgi@fntimes.com

기사입력 : 2026-04-14 09:03

Cumulative TSR improves as return policies take effect, supported by core business competitiveness

Recreated with generative AI based on Korea Financial Times content

Recreated with generative AI based on Korea Financial Times content

이미지 확대보기
[Korea Financial Times, Park seulgi] Retail stocks are a textbook example of an undervalued sector in the stock market, largely because investors remain skeptical about their growth potential.

As the leading player in South Korea's retail industry, E-mart has not been immune to this stigma of low corporate valuations and depressed share prices.

Recently, however, the company has been shifting the narrative through aggressive shareholder return policies. Observers say Emart is leading a turnaround for retail stocks, breaking free from the shackles of undervaluation.

On April 12, the Korea Financial Times calculated total shareholder return (TSR) using the corporate data platform DeepSearch, covering the period from January 2, 2024 to the last trading day of December 2025. TSR is a metric derived by adding share price fluctuations and dividend yields over a given period and dividing the sum by market capitalization, representing the total return an investor can earn from holding a company's stock.

Based on this calculation, Emart's cumulative TSR came in at 11.07%. In practical terms, a KRW 10 million investment in Emart shares at the start of 2024 would now be worth approximately KRW 11.1 million.

By comparison, Lotte Shopping — another major retailer — posted a cumulative TSR of just 2.83% over the same period. With the broader retail sector continuing to trade at undervalued levels, Emart's relatively strong return stands out.

The contrast becomes even more striking when compared with the preceding period.

From January 2, 2023 to the end of December 2024, Emart's TSR was negative 31.01%, meaning a KRW 10 million investment would have shrunk to approximately KRW 6.9 million. The divergence in outcomes depending on the investment timing was stark: those who invested a year earlier suffered losses exceeding KRW 3 million, while those who invested later reaped gains of more than KRW 1 million.

A Dramatic Turnaround in Investment Returns — Why?

Behind Emart's TSR improvement lies an aggressive shareholder return policy. Analysts say the company drove its share price higher by simultaneously expanding dividends and canceling treasury shares to enhance shareholder value.

In the past, Emart's shareholder return policy focused on maintaining stable dividends. Through 2023, the company merely maintained a minimum dividend of KRW 2,000 per share regardless of earnings performance, with limited additional return measures such as treasury share cancellations.

However, as the government's Corporate Value-up initiative gained prominence in 2024, Emart significantly bolstered its shareholder returns.

From 2025 through 2027, the company raised its minimum dividend per share by 25%, from KRW 2,000 to KRW 2,500, and committed to investing an additional KRW 13.4 billion annually to fund the dividend increase.

Treasury share cancellations are also underway. Emart laid out a plan to retire more than 50% of its treasury stock holdings over two years from 2025 to 2026, canceling 280,000 shares per year for a total of 560,000 shares — equivalent to approximately 2% of total outstanding shares. As of last year, Emart's treasury share holdings stood at 2.9% of total shares.

Emart's shareholder return policies were made possible by its stable cash-generating capacity. Despite recording a loss in 2023, the company maintained operating cash flow of KRW 1.13 trillion. It subsequently generated KRW 1.45 trillion in 2024 and KRW 1.32 trillion in 2025, sustaining cash flows above KRW 1 trillion for three consecutive years.

This robust cash generation base is what enabled the aggressive shareholder return policies — including dividend increases and treasury share cancellations — ultimately driving the improvement in TSR, according to analysts.

Core Business Competitiveness Strengthened: Earnings Turnaround Also Plays a Part

The company's efforts to reinforce its core business competitiveness also appear to have played a role.

In 2023, Emart reported an operating loss of KRW 46.9 billion — its first-ever deficit — largely attributable to weakness in its flagship hypermarket operations and deteriorating results at Shinsegae Engineering & Construction.

In 2024, while revenue declined 1.5% year-over-year to KRW 29.0209 trillion, operating profit reached KRW 47.1 billion, an improvement of KRW 94 billion from the previous year.

In 2025, revenue edged down 0.2% to KRW 28 trillion, but operating profit surged 584.8% to KRW 322.5 billion, marking a dramatic improvement in profitability. To improve margins, Emart aggressively pursued operational efficiencies, including organizational streamlining through voluntary retirement programs, integrated procurement across its three offline banners — Emart, Emart Everyday, and Emart24 — and logistics optimization.

While trimming excess, the company doubled down on strengthening its core retail operations.

It opened a series of specialty stores, including Starfield Market locations, Food Market outlets, and warehouse-style discount stores under the Traders brand.

The company sought differentiation through stores tailored to local characteristics and consumer environments. In response to persistently high inflation, it actively invested in value-oriented initiatives, including the budget private-label brand 5K PRICE, the ultra-low-price in-store shop WOW SHOP, and the large-scale promotional campaign Goraeit Festa (a wordplay on the English word "great").

Indeed, Emart's cash used in investing activities reached negative KRW 1.0695 trillion in 2025.

Compared with negative KRW 892.1 billion in 2024 and negative KRW 809.1 billion in 2023, investment spending increased substantially. Industry observers believe that while the strengthening of core business competitiveness and the resulting earnings recovery provided a floor for the stock price, the shareholder return policies served to lift the company's valuation.

An industry insider said, "Emart is a case where an earnings turnaround, core business competitiveness enhancement, and shareholder return policies all converged to push up both the share price and investment returns," adding, "The market's assessment appears to have changed because this was accompanied by fundamental structural improvement, rather than a one-off event."

Park seulgi (seulgi@fntimes.com)

데일리 금융경제뉴스 FNTIMES - 저작권법에 의거 상업적 목적의 무단 전재, 복사, 배포 금지
Copyright ⓒ 한국금융신문 & FNTIMES.com

가장 핫한 경제 소식! 한국금융신문의 ‘추천뉴스’를 받아보세요~

KFT Topic 다른 기사

1 Kia's Three Growth Engines Fuel Its Historic Charge Toward No. 1 The long-standing formula of South Korea's auto market — Hyundai Motor No. 1, Kia No. 2 — is showing cracks. Kia has narrowed the sales gap with Hyundai Motor to within striking distance, and forecasts that it will claim the top spot in domestic sales for the first time in its history this year are increasingly becoming reality.Kia's sales momentum is attributed to solid performance in its core SUV lineup, combined with the successful rollout of new lineups such as mass-market electric vehicle (EV) models and purpose-built vehicles (PBVs).According to Kia's disclosure on the 28th, the compan 2 SK Biopharmaceuticals Doubles Down: $795M Bet on Second Blockbuster Epilepsy Drug "SK Biopharmaceuticals has now entered a different league, one in which we compete directly with global big pharma companies in the United States and Europe, not just in Korea."President Lee Dong-hoon of SK Biopharmaceuticals made this declaration at a press conference held on the afternoon of the 26th at the Westin Josun Hotel in Jung-gu, Seoul, where he abruptly unveiled the company's license-in (L/I) agreement to acquire opakalim, an epilepsy drug candidate from Ireland-based Biohaven.Through the deal, SK Biopharmaceuticals aims to reduce its reliance on a single product — cenobamate — an 3 Naver Bets on AI Infrastructure While Kakao Bets on Agentic AI South Korea's two leading platform companies, Naver and Kakao, are maintaining similar levels of research and development (R&D) investment relative to revenue in the first half of this year, but they are pursuing markedly different strategies to secure AI competitiveness.Naver is focused on expanding AI infrastructure, while Kakao — taking its spinoff as an opportunity — is concentrating on strengthening agentic AI services.According to the Financial Supervisory Service's electronic disclosure system on the 24th, Naver's and Kakao's R&D spending in the first half of 2026 came to KRW
ad
ad
ad

한국금융 포럼 사이버관

더보기

FT카드뉴스

더보기
[그래픽 뉴스] ISA 대개편! 나에게 유리한 계좌는?
[그래픽 뉴스] 미국 증시 새로운 키워드 'MANGOS'
환전·로또·육아휴직까지 하반기부터 달라지는 제도 TOP11
[그래픽 뉴스] 은퇴후 30년 부모님 세대의 생존전략
[그래픽 뉴스] 퇴근 후 주차했는데 수익 발생? V2G의 정체

FT도서

더보기